A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. Our clinical programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need. The successful development of the clinical pipeline is supported by our internal end-to-end manufacturing capabilities. We have two viral vector production facilities for good manufacturing practices, or GMP, internal plasmid production for GMP, as well as an in-house Quality Control hub for stability and release, all fit for Investigational New Drug application (IND) through commercial supply. In addition, we have developed a proprietary manufacturing platform with leading yield and quality aspects and commercial readiness.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -169M | -148M | -84M | -130M | -80M | -58M |
| EPS | $-2.11 | $-2.12 | $-1.49 | $-2.87 | $-1.80 | $-1.54 |
| Free Cash Flow | -121M | -109M | -126M | -118M | -57M | -85M |
| ROIC | -68.4% | -347.0% | -40.0% | -3700.5% | -42.7% | -24.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 1.08 | 0.52 | 0.00 | 0.01 | 0.52 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -164M | -164M | -137M | -116M | -73M | -63M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | 0.0% | -143.5% | -60.8% | -85.5% | -42.9% | -24.3% |
| Shares Outstanding | 80M | 70M | 56M | 45M | 44M | 38M |
| Metric | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -58M | -63M | -73M | -116M | -137M | -164M | -164M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -55M | -58M | -80M | -130M | -84M | -148M | -169M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -28.7% | -24.3% | -42.7% | N/M | -40.0% | N/M | -68.4% |
| ROE | -28.7% | -24.3% | -42.9% | -85.5% | -60.8% | -143.5% | 0.0% |
| ROA | -16.9% | -15.9% | -24.9% | -40.6% | -25.7% | -49.6% | -89.0% |
| Cash Flow | |||||||
| Op. Cash Flow | 20M | -64M | -11M | -73M | -105M | -104M | -116M |
| Free Cash Flow | 11M | -85M | -57M | -118M | -126M | -109M | -121M |
| Owner Earnings | 1.9M | -87M | -39M | -110M | -147M | -143M | -154M |
| CapEx | 9.0M | 21M | 46M | 45M | 20M | 5.0M | 4.8M |
| Maint. CapEx | 2.2M | 4.2M | 7.9M | 8.7M | 14M | 13M | 13M |
| Growth CapEx | 6.7M | 17M | 38M | 36M | 6.4M | 0 | 0 |
| D&A | 2.2M | 4.2M | 7.9M | 8.7M | 14M | 13M | 13M |
| CapEx/OCF | 44.8% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 16M | 18M | 21M | 29M | 28M | 25M | 25M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | N/A | N/A | -137M | -115M | -57M | -30M | -15M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | 15M |
| Long-Term Debt | N/A | N/A | 953K | 262K | 72M | 73M | 73M |
| Debt/Equity | 0.70 | 0.52 | 0.01 | 0.00 | 0.52 | 1.08 | 0.00 |
| Interest Coverage | -1198.6 | -450.0 | -252.6 | -23.5 | -10.3 | -12.4 | -12.4 |
| Equity | 191M | 239M | 185M | 118M | 138M | 68M | -41M |
| Total Assets | 324M | 364M | 320M | 318M | 327M | 270M | 189M |
| Total Liabilities | 133M | 125M | 135M | 200M | 189M | 202M | 230M |
| Intangibles | N/A | 4.2M | 3.6M | 2.7M | 2.2M | 1.6M | 1.6M |
| Retained Earnings | -203M | -261M | -341M | -470M | -554M | -702M | -702M |
| Working Capital | 220M | 218M | 115M | 72M | 93M | 63M | 63M |
| Current Assets | 269M | 273M | 183M | 154M | 160M | 124M | 124M |
| Current Liabilities | 49M | 54M | 68M | 82M | 67M | 61M | 61M |
| Per Share Data | |||||||
| EPS | -1.65 | -1.54 | -1.80 | -2.87 | -1.49 | -2.12 | -2.11 |
| Owner EPS | 0.06 | -2.30 | -0.89 | -2.45 | -2.60 | -2.04 | -1.92 |
| Book Value | 5.75 | 6.34 | 4.19 | 2.61 | 2.45 | 0.97 | -0.50 |
| Cash Flow/Share | 0.60 | -1.70 | -0.24 | -1.62 | -1.87 | -1.50 | -1.94 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 33.2M | 37.7M | 44.2M | 45.2M | 56.4M | 69.7M | 80.5M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -5.4 |
| P/FCF | 60.3 | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 3.5 | 2.6 | 5.5 | 2.3 | 2.9 | 6.4 | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | 1.7% | -13.8% | -5.6% | -43.4% | -31.3% | -25.3% | -13.3% |
| Market Cap | 668M | 616M | 1.0B | 272M | 402M | 433M | 909M |
| Avg. Price | 18.75 | 14.55 | 15.60 | 10.41 | 6.09 | 5.38 | 11.29 |
| Year-End Price | 20.12 | 16.35 | 23.14 | 6.03 | 7.12 | 6.21 | 11.29 |
MeiraGTx Holdings plc passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -4.0%.
MeiraGTx Holdings plc (MGTX) has a 5-year average return on invested capital (ROIC) of -35.7%. This is below average and may indicate limited pricing power.
MeiraGTx Holdings plc (MGTX) has a market capitalization of $909M. It is classified as a small-cap stock.
MeiraGTx Holdings plc (MGTX) does not currently pay a regular dividend.
MeiraGTx Holdings plc (MGTX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
MeiraGTx Holdings plc (MGTX) generated $-109 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
MeiraGTx Holdings plc (MGTX) has a debt-to-equity ratio of 1.08. This indicates moderate leverage.
MeiraGTx Holdings plc (MGTX) reported earnings per share (EPS) of $-2.12 in its most recent fiscal year.
MeiraGTx Holdings plc (MGTX) has a return on equity (ROE) of -143.5%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for MeiraGTx Holdings plc (MGTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
MeiraGTx Holdings plc (MGTX) has a book value per share of $0.97, based on its most recent annual SEC filing.
No recent press releases.